A study evaluating patients diagnosed with thyroid cancer who refused a clinical intervention for fear of being overdiagnosed has reported that the individuals feel isolated and anxious.
A study evaluating patients diagnosed with thyroid cancer who refused a clinical intervention for fear of being overdiagnosed has reported that the individuals feel isolated and anxious. Additionally, they are at a risk of disengaging from healthcare.
Cancer overdiagnosis has been a global concern among health services researchers. Improved diagnostic tools, increased patient awareness, and a greater emphasis on medical surveillance have together contributed to this phenomenon. Nearly 60% of thyroid cancers in developed nations were diagnosed because the population had access to better tools, which raises questions around increased regulation and consideration for watchful waiting, rather than treatment.
However, according to the current study published in JAMA Otolaryngology-Head and Neck Surgery, interviews with individuals who self-identified as being overdiagnosed and refused treatment identified feelings of anxiety and isolation. The study authors interviewed 22 individuals (range, 21-75 years), primarily female, who had been diagnosed with thyroid cancer—18 of them had refused an intervention and had been living with the decision for a median time of 39 months (range, 1-88 months).
Twelve of the 18 participants reported significant anxiety regarding their cancer progression, but explained that their decision was based on:
Twelve of them also reported absence of support from medical professionals, friends, and social media groups, including suggestions that they had made the wrong decision. Only 3 of the 18 said they had successfully connected with others about their experience, while 15 individuals had kept their diagnosis a secret. Five participants had disengaged themselves from medical surveillance, which is the recommended alternative to an active intervention for patients diagnosed with thyroid cancer.
The authors express concern that individuals diagnosed with thyroid cancer who choose nonintervention are at risk of disengaging from healthcare. They recommend lending social and health system support and education for this population to keep them engaged with their surveillance and ultimately, to promote quality healthcare.
“Culturally we are conditioned to think that if you’re diagnosed with cancer, you have to do everything you can to rid your body of that cancer. Changing attitudes toward non-intervention is likely to require a change in our larger social and media culture,” senior author Louise Davies, MD, MS, associate professor at The Dartmouth Institute and Chief of Otolaryngology at Veterans Administration in White River Junction, Vermont, said in a statement.
Reference
Davies L, Hendrickson CD, Hanson GS. Experience of US patients who self-identify as having an overdiagnosed thyroid cancer: a qualitative analysis [published online March 9, 2017]. JAMA Otolaryngol Head Neck Surg. doi: 10.1001/jamaoto.2016.4749.
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More